

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** Unknown  
**Gender:** Unknown  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Autoimmune Epilepsy Panel, CSF**

ARUP test code 3006205

NMDA Receptor Ab IgG CBA-IFA, CSF

**1:80** \* (Ref Interval: < 1:1)

Antibodies to NMDA were detected; titer was performed at an additional charge.

The EXTINGUISH Trial (safety and efficacy of Inebilizumab in anti-NMDA receptor encephalitis, NCT04372615) is actively recruiting patients. To learn more, or to refer your patient, call 1-844-427-2465, email EXTINGUISH@hsc.utah.edu, or visit <https://neuronext.org/projects/nn111-extinguish>.

INTERPRETIVE INFORMATION: NMDA Receptor Ab IgG CBA-IFA, CSF

NMDA receptor antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response. In addition, positive results have been reported in patients with non-autoimmune phenotypes. A negative test result does not rule out a diagnosis of autoimmune limbic encephalitis. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes full-length GluN1 transfected cell lines for the detection and semiquantification of NMDA receptor IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

**ANNA Detected** \* (Ref Interval: None Detected)

Antibodies detected, therefore IFA titer and Immunoblot testing to be performed.

INTERPRETIVE INFORMATION: Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**H=High, L=Low, \*=Abnormal, C=Critical**

**AMPA Receptor Ab IgG CBA-IFA Screen, CSF**

**Detected** \* (Ref Interval: < 1:1)

AMPA Receptor Antibody, IgG is detected. Titer results to follow.

INTERPRETIVE INFORMATION: AMPA Receptor Ab IgG CBA-IFA Screen, CSF

Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of autoimmune encephalitis. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes AMPAR transfected cell lines for detection and semiquantification of AMPAR IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**GABA-BR Ab IgG CBA-IFA Screen, CSF**

**Detected** \* (Ref Interval: < 1:1)

GABA-BR Antibody, IgG is detected. Titer results to follow.

INTERPRETIVE INFORMATION: GABA-BR Ab IgG CBA-IFA Screen, CSF

Gamma-amino butyric acid receptor, type B (GABA-BR) antibody is found in a subset of patients with autoimmune epilepsy and other autoimmune neurologic phenotypes; it may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes GABA-BR transfected cell lines for the detection and semiquantification of GABA-BR IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**CASPR2 Ab IgG CBA-IFA Screen, CSF**

**Detected** \* (Ref Interval: < 1:1)

CASPR2 Antibody, IgG is detected. Titer results to follow.

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION: CASPR2 Ab IgG CBA-IFA Screen, CSF

Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Tumors such as thymoma, small cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CASPR2 transfected cell lines for the detection and semiquantification of the CASPR2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

LGI1 Ab IgG CBA-IFA Screen, CSF

**Detected** \* (Ref Interval: < 1:1)

LGI1 Antibody, IgG is detected. Titer results to follow.

INTERPRETIVE INFORMATION: LGI1 Ab IgG CBA-IFA Screen, CSF

Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia, and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes LGI1 transfected cell lines for the detection and semi-quantification of the LGI1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CV2 Ab IgG CBA-IFA Screen, CSF

**Detected** \* (Ref Interval: < 1:1)

CV2 Antibody, IgG is detected. Titer results to follow. Additional charges apply.

H=High, L=Low, \*=Abnormal, C=Critical

**INTERPRETIVE INFORMATION: CV2 Ab IgG CBA-IFA Screen, CSF**

CV2 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CV2 transfected cell lines for the detection and semiquantification of the CV2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**SOX1 Antibody, IgG by Immunoblot, CSF**

**High Positive \* (Ref Interval: Negative)**

**INTERPRETIVE INFORMATION: SOX1 Antibody, IgG by Immunoblot, CSF**

SOX1 antibody is detected in patients with Lambert-Eaton myasthenic syndrome (LEMS) and in patients with paraneoplastic cerebellar degeneration (PCD), paraneoplastic and nonparaneoplastic neuropathy. SOX1 antibody is associated with small cell lung cancer. A negative test result does not rule out a diagnosis of LEMS or other causes of paraneoplastic neurological syndrome.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**Amphiphysin Antibody, CSF**

**Positive \* (Ref Interval: Negative)**

**INTERPRETIVE INFORMATION: Amphiphysin Antibody IgG, CSF**

Amphiphysin antibody is present in about 5 percent of patients with stiff-person syndrome and is found variably in other causes of paraneoplastic neurological syndrome (PNS). Amphiphysin antibody is mainly associated with small-cell lung cancer and breast tumors.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**DPPX Ab IgG CBA-IFA Screen, CSF**

**Detected \* (Ref Interval: < 1:1)**

DPPX Antibody, IgG is detected. Titer results to follow.

**H=High, L=Low, \*=Abnormal, C=Critical**

**INTERPRETIVE INFORMATION: DPPX Ab IgG CBA-IFA Screen, CSF**

DPPX antibody is found in a subset of patients with autoimmune encephalitis, and is often associated with prodromal gastrointestinal symptoms and unintentional weight loss. It may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes DPPX transfected cells for the detection and semiquantification of the DPPX IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**GABA-AR Ab IgG CBA-IFA Screen, CSF**

**Detected \* (Ref Interval: < 1:1)**

GABA-AR Antibody, IgG is detected. Titer results to follow.

**INTERPRETIVE INFORMATION: GABA-AR Ab IgG CBA-IFA Screen, CSF**

Gamma-aminobutyric acid receptor, type A (GABA-AR) antibody is found in a subset of patients with autoimmune encephalitis or autoimmune epilepsy, and may occur with or without associated tumor. A negative test result does not rule out a diagnosis of autoimmune limbic encephalitis or autoimmune epilepsy. Interpretation of any anti-neural antibody test requires clinical correlation.

This indirect fluorescent antibody assay utilizes GABA-AR transfected cell lines for detection and semi-quantification of GABA-AR IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**mGluR1 Ab IgG CBA-IFA Screen, CSF**

**Detected \* (Ref Interval: < 1:1)**

mGluR1 Antibody, IgG is detected. Titer results to follow.

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION: mGluR1 Ab IgG CBA-IFA Screen, CSF

Metabotropic glutamate receptor 1 (mGluR1) antibody is found in a subset of patients with autoimmune cerebellar ataxia or autoimmune encephalitis and may occur with or without associated tumor. A negative test result does not rule out a diagnosis of autoimmune cerebellar ataxia or limbic encephalitis. Interpretation of any anti-neural antibody test requires clinical correlation.

This indirect fluorescent antibody assay utilizes mGluR1 transfected cell lines for detection and semi-quantification of mGluR1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Glutamic Acid Decarboxylase Antibody CSF

**10.0 IU/mL H (Ref Interval: 0.0-5.0)**

INTERPRETIVE INFORMATION: Glutamic Acid Decarboxylase Antibody, CSF

A value greater than 5.0 IU/mL is considered positive for glutamic acid decarboxylase antibody (GAD AB CSF).

This assay is intended for the semi-quantitative determination of the GAD Ab in human CSF. Results should be interpreted within the context of clinical symptoms.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Neuronal Nuclear Antibody (ANNA) IFA Titer, IgG, CSF (Do NOT give this test code to clients - Panel Component ONLY. Refer to 2010841.)**

ARUP test code 2010843

Neuronal Nuclear Ab Titer, IgG CSF

**1:20 \* (Ref Interval: < 1:1)**

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab Titer, IgG CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody Titer, IgG by CBA-IFA, CSF (Reflex of 3001257 AMPA CSF - Not orderable by clients)**

ARUP test code 3001263

AMPA Receptor Ab IgG CBA-IFA Titer, CSF

**1:40 \* (Ref Interval: < 1:1)**

H=High, L=Low, \*=Abnormal, C=Critical

INTERPRETIVE INFORMATION: AMPA Receptor Ab IgG CBA-IFA  
Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Gamma Aminobutyric Acid Receptor, Type B (GABA-BR) Antibody Titer, IgG by CBA-IFA, CSF (Reflex of 3001267 GABA CSF - Not orderable by clients)**

ARUP test code 3001273

GABA-BR Ab IgG CBA-IFA Titer, CSF

**1:40** \* (Ref Interval: < 1:1)

INTERPRETIVE INFORMATION: GABA-BR Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Contactin-Associated Protein-2 Antibody Titer, IgG by CBA-IFA, CSF (Reflex of CASPR2GCSF Only - Not Orderable by Clients)**

ARUP test code 3001989

CASPR2 Ab IgG CBA-IFA Titer, CSF

**1:80** \* (Ref Interval: < 1:1)

INTERPRETIVE INFORMATION: CASPR2 Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Leucine-Rich, Glioma-Inactivated Protein 1 Antibody Titer, IgG by CBA-IFA, CSF (Reflex for LGI1 IGG CSF Only - Not Orderable by Clients)**

ARUP test code 3001994

LGI1 Ab IgG CBA-IFA Titer, CSF

**1:40** \* (Ref Interval: < 1:1)

INTERPRETIVE INFORMATION: LGI1 Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**CV2 Antibody Titer, IgG by CBA-IFA, CSF (Reflex for 3017001 CV2 CSF - Not orderable by clients)**

ARUP test code 3017002

CV2 Ab IgG CBA-IFA Titer, CSF

**1:40** \* (Ref Interval: < 1:1)

H=High, L=Low, \*=Abnormal, C=Critical

INTERPRETIVE INFORMATION: CV2 Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot, CSF**

ARUP test code 3004527

Neuronal Nuclear Ab (Hu) IgG, IB, CSF

**High Positive** \* (Ref Interval: Negative)

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Hu) IgG, IB, CSF

This test detects IgG antineuronal antibodies to Hu, Ri, and Yo and Tr (DNER) antigens.

Antineuronal antibodies serve as markers that aid in discriminating between a true paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-Hu (antineuronal nuclear antibody, type I) is associated with small cell lung cancer. Anti-Ri (antineuronal nuclear antibody, type II) is associated with neuroblastoma in children and with fallopian tube and breast cancer in adults. Anti-Yo (anti-Purkinje cell cytoplasmic antibody) is associated with ovarian and breast cancer. Anti-Tr(DNER) is associated with Hodgkin's lymphoma.

The presence of one or more of these antineuronal antibodies supports a clinical diagnosis of PND and should lead to a focused search for the underlying neoplasm.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Neuronal Nuclear Ab (Ri) IgG, IB, CSF

**Positive** \* (Ref Interval: Negative)

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Ri) IgG, IB, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Neuronal Nuclear Ab (Yo) IgG, IB, CSF

**Positive** \* (Ref Interval: Negative)

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Yo) IgG, IB, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Neuronal Nuclear Ab (TR/DNER) IgG, CSF

**High Positive** \* (Ref Interval: Negative)

H=High, L=Low, \*=Abnormal, C=Critical

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (TR/DNER)  
IgG, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Dipeptidyl Aminopeptidase-Like Protein 6 (DPPX) Antibody Titer, IgG by CBA-IFA, CSF (Reflex of 3004512 DPPX CSF - Not orderable by clients)**

ARUP test code 3004515

DPPX Ab IgG CBA-IFA Titer, CSF

**1:20 \***

**(Ref Interval: < 1:1)**

INTERPRETIVE INFORMATION: DPPX Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Gamma-Aminobutyric Acid Receptor, Type A (GABA-AR) Antibody Titer, IgG by CBA-IFA, CSF (Reflex of GABA-A CSF - Not Orderable by Clients)**

ARUP test code 3006006

GABA-AR Ab IgG CBA-IFA Titer, CSF

**1:80 \***

**(Ref Interval: < 1:1)**

INTERPRETIVE INFORMATION: GABA-AR Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**Metabotropic Glutamate Receptor 1 (mGluR1) Antibody Titer, IgG by CBA-IFA, CSF (Reflex of MGLUR1 CSF - Not Orderable by Clients)**

ARUP test code 3006042

mGluR1 Ab IgG CBA-IFA Titer, CSF

**1:80 \***

**(Ref Interval: < 1:1)**

INTERPRETIVE INFORMATION: mGluR1 Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**H=High, L=Low, \*=Abnormal, C=Critical**

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
NMDA Receptor Ab IgG CBA-IFA, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab Titer, IgG CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Paraneoplastic Abs (PCCA/ANNA) IgG, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
AMPA Receptor Ab IgG CBA-IFA Screen, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
AMPA Receptor Ab IgG CBA-IFA Titer, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GABA-BR Ab IgG CBA-IFA Screen, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GABA-BR Ab IgG CBA-IFA Titer, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CASPR2 Ab IgG CBA-IFA Screen, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CASPR2 Ab IgG CBA-IFA Titer, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
LG11 Ab IgG CBA-IFA Screen, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
LG11 Ab IgG CBA-IFA Titer, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CV2 Ab IgG CBA-IFA Screen, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CV2 Ab IgG CBA-IFA Titer, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SOX1 Antibody, IgG by Immunoblot, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Hu) IgG, IB, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Ri) IgG, IB, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Yo) IgG, IB, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Amphiphysin Antibody, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
DPPX Ab IgG CBA-IFA Screen, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
DPPX Ab IgG CBA-IFA Titer, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (TR/DNER) IgG, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GABA-AR Ab IgG CBA-IFA Screen, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GABA-AR Ab IgG CBA-IFA Titer, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
mGluR1 Ab IgG CBA-IFA Screen, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
mGluR1 Ab IgG CBA-IFA Titer, CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Glutamic Acid Decarboxylase Antibody CSF	24-057-100505	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 24-057-100505  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 10 of 10 | Printed: 2/26/2024 11:25:13 AM  
4848